Study Suggests Blood Test Trends Could Indicate Cancer Risk Before Symptoms Appear
In primary care, blood test abnormalities are often considered in cancer risk assessments, but traditionally, the focus has been on whether individual test results are abnormal at a specific point in time. A recent study published in PLOS Medicine highlights the potential benefits of monitoring changes in blood test results over time, suggesting this approach may be more effective for assessing cancer risk than relying solely on the most recent test results. The research involved a substantial cohort of 275,205 patients who presented with unexplained weight loss, a symptom that can indicate cancer. Among these patients, nearly 14,000 received a cancer diagnosis within six months of their initial presentation. The study aimed to determine whether trends in 26 common blood tests could aid in earlier cancer diagnosis. According to study author Pradeep Virdee, monitoring how a patient’s blood test results change over time could provide valuable insights. The researchers examined trends over one, three, six, and ten years prior to the patients presenting with unexplained weight loss. They discovered that for those who later developed cancer, notable changes in blood tests typically began to occur three to five years before the onset of weight loss. Interestingly, these changes often remained within normal reference ranges, indicating that subtle shifts could be significant indicators of risk. The study's authors also adjusted blood test abnormalities and trends for sex and age, finding that the area under the curves (AUCs) improved in 34 instances when compared to unadjusted estimates, with the highest AUC reaching 0.82. This suggests a strong ability to discriminate between those at risk and those not at risk. Brian Nicholson, another study author, emphasized the importance of considering patient age and sex when interpreting results, rather than solely relying on laboratory reference ranges. Ketan Thanki, a colorectal surgeon, commented on the findings, noting that unexplained weight loss accompanied by abnormal blood test results is a significant cancer signal, with about five percent of such patients diagnosed with cancer within six months. He advocated for comparing a patient’s values against their own historical data rather than just against reference values. The study authors identified that certain blood tests, including hemoglobin, white blood cell count, and platelets, are not only commonly available but also serve as effective markers for inflammatory states and nutritional deficits that may be linked to cancer. Thanki suggested that additional markers, such as C-reactive protein and albumin, could enhance the assessment of cancer risk. Unexplained weight loss is a nonspecific symptom that can lead to delays in diagnosis, making it a crucial trigger for monitoring blood test trends. Thanki pointed out that while monitoring can be beneficial, it may also lead to false alarms and unnecessary investigations if applied too broadly. The study's limitations include the potential for bias in the data, as it only analyzed patients who had multiple blood tests within the relevant time frames. Despite these limitations, the authors believe that monitoring trends in blood tests could provide valuable information about cancer risk, particularly within the last year of testing. They concluded that external validation and demonstrating significant clinical improvements will be essential for implementing this approach in clinical practice.




